Skip to main content

Advertisement

SpringerLink
Log in

Probiotika

Mikrobiommodulation

  • fortbildung
  • Published:
Gastro-News Aims and scope

Es gibt heute zahlreiche wissenschaftliche Untersuchungen zu oralen Probiotika bei unterschiedlichen Erkrankungen sowie zu deren Wirkmechanismen. Inzwischen ist bekannt, dass die Wirksamkeit von probiotischen Bakterien sowohl stamm- als auch krankheitsspezifisch ist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. McFarland LV et al. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2018;5:124

    Article  Google Scholar 

  2. Sniffen JC et al. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018; 13(12): e0209205

    Article  CAS  Google Scholar 

  3. Piche T. Tight junctions and IBS—the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296–302.

    Article  CAS  Google Scholar 

  4. Lacy BE et al. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017;6(11):99.

    Article  Google Scholar 

  5. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133–146

    Article  Google Scholar 

  6. Stern EK & Brenner DM. Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2018;9(2):e134.

    Article  Google Scholar 

  7. Lazaridis N, Germanidis G. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann Gastroenterol. 2018;31(2):171–187.

    PubMed  PubMed Central  Google Scholar 

  8. Layer P et al. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol 2011;49:237–293.

    Article  CAS  Google Scholar 

  9. Ducrotte P et al. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012; 18(30) 4012–4018.

    Article  CAS  Google Scholar 

  10. Ambrosetti P, Chautems R, Soravia C, et al.: Long-term outcome of mesocolic and pelvic diverticular abscesses of the left colon: a prospective study of 73 cases. Dis Colon Rectum 2005;48:787–791.

    Article  Google Scholar 

  11. Leifeld L et al. 1S2k Leitlinie Divertikelkrankheit / Divertikulitis. AWMF-Registernummer 021/20.

  12. Tursi A et al. Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: a comparison with fecal calprotectin in clinical setting. J Clin Gastroenterol. 2015;49(3):218–21.

    Article  Google Scholar 

  13. Scarpignato et al. Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. Therap Adv Gastroenterol. 2018;11:1756284818771305.

    Article  Google Scholar 

  14. Maconi. Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. Acta Biomed. 2017; 88(1): 25–32

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Barbara G et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut. 2017;66(7):1252–1261.

    Article  CAS  Google Scholar 

  16. Tursi A et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease—a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013;38(7):741–51.

    Article  CAS  Google Scholar 

  17. Lübbert et al., Dtsch Med Wochenschr 2018

    Google Scholar 

  18. Lübbert C et al. Clostridium-difficile-Infektion. Leitliniengerechte Diagnostik- und Behandlungsoptionen. Dtsch Arztebl Int 2014; 111(43): 723–31.

    PubMed  PubMed Central  Google Scholar 

  19. Grube RF et al. Ökonomische Auswirkungen einer Clostridium-difficile-Enterokolitis in deutschen Krankenhäusern auf der Basis von DRG-Kostendaten. Z Gastroenterol 2015; 53: 391–39.

    Article  CAS  Google Scholar 

  20. Goldenberg JZ et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017 Dec 19;12.

  21. Shen NT et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017 Jun;152(8):1889–1900.e9.

    Article  Google Scholar 

  22. Gao XW et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010 Jul;105(7):1636–41.

    Article  Google Scholar 

  23. Maziade PJ et al. A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis. 2015 May 15;60 Suppl 2:S144–7.

    Article  CAS  Google Scholar 

  24. Kamdeu Fansi AA et al. Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. J Med Econ. 2012;15(1):53–60.

    Article  Google Scholar 

  25. Meyer EA et al. Gut Microbes and the Brain: Paradigm Shift in Neuroscience. J Neurosci. 2014 Nov 12;34(46):15490–15496.

    Article  Google Scholar 

  26. Klimovich AV et al. Rethinking the Role of the Nervous System: Lessons From the Hydra Holobiont. Bioessays. 2018 Sep;40(9):e1800060.

    Article  Google Scholar 

  27. Yano JM et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015 Apr 9;161(2):264–76.

    Article  CAS  Google Scholar 

  28. Emeran Mayer, Das zweite Gehirn, riva Verlag, 2. Auflage 2017

    Google Scholar 

  29. How microbes could cure disease: Rob Knight at TED2014. TED Blog 2014 Mar 19.

  30. Tillisch K et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013 Jun;144(7):1394–401, 1401.e1-4.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diakonie Klinikum, Jung-Stilling-Krankenhaus Akademisches Lehrkrankenhaus der Universität Marburg, Wichernstraße 40, 57074, Siegen, Deutschland

    Joachim Labenz

Authors
  1. Joachim Labenz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joachim Labenz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Labenz, J. Mikrobiommodulation. Gastro-News 6, 48–50 (2019). https://doi.org/10.1007/s15036-019-0691-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-019-0691-4

Search

Navigation